Lineage Cell Therapeutics, Inc. Annual Operating Lease, Payments in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
Lineage Cell Therapeutics, Inc. quarterly/annual Operating Lease, Payments history and growth rate from 2019 to 2023.
  • Lineage Cell Therapeutics, Inc. Operating Lease, Payments for the quarter ending March 31, 2024 was $302K, a 4.13% decline year-over-year.
  • Lineage Cell Therapeutics, Inc. annual Operating Lease, Payments for 2023 was $1.13M, a 7.83% increase from 2022.
  • Lineage Cell Therapeutics, Inc. annual Operating Lease, Payments for 2022 was $1.05M, a 12% increase from 2021.
  • Lineage Cell Therapeutics, Inc. annual Operating Lease, Payments for 2021 was $935K, a 31% decline from 2020.
Operating Lease, Payments, Annual (USD)
Operating Lease, Payments, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $1.13M +$82K +7.83% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-07
2022 $1.05M +$112K +12% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-07
2021 $935K -$421K -31% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-09
2020 $1.36M -$8K -0.59% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-10
2019 $1.36M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.